- Home
- UCL vs PRLD Comparison
UCL vs PRLD Comparison
Compare UCL & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- PRLD
- Stock Information
- Founded
- UCL 2014
- PRLD 2016
- Country
- UCL Hong Kong
- PRLD United States
- Employees
- UCL N/A
- PRLD N/A
- Industry
- UCL Telecommunications Equipment
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- UCL Consumer Discretionary
- PRLD Health Care
- Exchange
- UCL Nasdaq
- PRLD Nasdaq
- Market Cap
- UCL 48.7M
- PRLD 53.4M
- IPO Year
- UCL 2020
- PRLD 2020
- Fundamental
- Price
- UCL $2.13
- PRLD $1.30
- Analyst Decision
- UCL
- PRLD Buy
- Analyst Count
- UCL 0
- PRLD 3
- Target Price
- UCL N/A
- PRLD $4.33
- AVG Volume (30 Days)
- UCL 378.8K
- PRLD 683.5K
- Earning Date
- UCL 11-26-2024
- PRLD 02-13-2025
- Dividend Yield
- UCL N/A
- PRLD N/A
- EPS Growth
- UCL 169.91
- PRLD N/A
- EPS
- UCL 0.11
- PRLD N/A
- Revenue
- UCL $87,405,000.00
- PRLD $3,000,000.00
- Revenue This Year
- UCL $11.23
- PRLD N/A
- Revenue Next Year
- UCL $27.52
- PRLD N/A
- P/E Ratio
- UCL $18.91
- PRLD N/A
- Revenue Growth
- UCL 4.73
- PRLD N/A
- 52 Week Low
- UCL $0.97
- PRLD $0.80
- 52 Week High
- UCL $3.30
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- UCL 62.21
- PRLD 63.10
- Support Level
- UCL $1.41
- PRLD $0.85
- Resistance Level
- UCL $3.30
- PRLD $1.00
- Average True Range (ATR)
- UCL 0.39
- PRLD 0.13
- MACD
- UCL 0.11
- PRLD 0.05
- Stochastic Oscillator
- UCL 45.33
- PRLD 77.03
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc provides mobile data connectivity and portable WiFi services. The business operates under uCloudlink 1.0, which focuses on cross-border travelers that need mobile data connectivity services across different countries. Under uCloudlink 2.0, provides mobile data connectivity services to local users across different MNOs in a single country. It generates revenue from the provision of data connectivity services, and the sales of terminals and sales of data related products.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.